04:27 PM EDT, 06/13/2025 (MT Newswires) -- InnoCan Pharma ( INNPF ) after close of trade Friday highlighted a "breakthrough narrative" in a recent article on the therapeutic potential of long-acting synthetic cannabidiol (CBD) for chronic pain.

The third-party publication of a peer-reviewed narrative review in Cureus journal titled "Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review," examines the global need for safer, more effective treatments of chronic pain.

The U.S. Food and Drug Administration (FDA) has emphasized the "critical need for new, non-addictive pain therapies," and Innocan has initiated regulatory submissions in support of advancing LPT-CBD into human clinical trials.

"We are thrilled by this breakthrough publication," said Chief Executive Officer Iris Bincovich. "Innocan is fully committed to advancing LPT-CBD toward clinical development, with the goal of delivering an innovative and safe non-opioid analgesic solution for chronic pain management."

Innocan closed trading unchanged at $0.17 a share on the Canadian Securities Exchange..